0000000000761801

AUTHOR

Uwe Mittler

showing 2 related works from this author

A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma

2012

Due to the lacking specificity of symptoms making a correct diagnosis can be a challenge in children with medulloblastoma. This can lead to prediagnostic symptomatic intervals (PSIs) of several weeks to months. It is unknown whether the length of the PSI is associated with an inferior survival outcome in this population.To study the association of PSI with disease stage at diagnosis, tumour control and survival in children with medulloblastoma, prospectively collected data on PSI, clinical, and biological features were analysed in 224 patients diagnosed at the age of 3-18 years and treated within the prospective randomised multicentre trial HIT'91.Patients with lower-stage disease tended to…

MaleCancer ResearchPediatricsmedicine.medical_specialtyDelayed DiagnosisTime FactorsAdolescentPopulation610 Medicine & healthDiseaselaw.inventionRandomized controlled triallawChildhood MedulloblastomaHumansMedicine1306 Cancer ResearchAge of OnsetStage (cooking)Cerebellar NeoplasmsChildeducationMedulloblastomaeducation.field_of_studybusiness.industryCancerPrognosismedicine.diseaseOncology10036 Medical ClinicChild PreschoolFemale2730 OncologyAge of onsetbusinessMedulloblastomaEuropean Journal of Cancer
researchProduct

Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT‘91

2009

PURPOSE: To analyse long-term outcome and clinical prognostic factors in medulloblastoma. METHODS: We analysed 280 patients with medulloblastoma (3-18 years) included from 1991 to 1997 in the randomised multicentre trial HIT'91 comparing pre-('sandwich') and postradiation ('maintenance') chemotherapy (median follow-up of survivors for 10 years). RESULTS: In 187 patients with complete staging, overall survival (OS) was higher after maintenance compared to sandwich treatment for M0 (10-year OS 91% and 62%, p=0.001) and M1 patients (10-year OS 70% and 34%, p=0.020). In M2/3 disease, 10-year OS was 42% and 45%. Incomplete staging, metastases, younger age and sandwich chemotherapy were independe…

MaleCancer ResearchVincristinePediatricsmedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmentAntineoplastic AgentsDrug Administration Schedulelaw.inventionMaintenance therapyRandomized controlled triallawmedicineHumansCerebellar NeoplasmsChildSurvival rateNeoplasm StagingProportional Hazards ModelsMedulloblastomaChemotherapybusiness.industryProportional hazards modelNeoplasms Second Primarymedicine.diseaseCombined Modality TherapySurvival RateClinical trialTreatment OutcomeOncologyVincristineChild PreschoolFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesMedulloblastomamedicine.drugEuropean Journal of Cancer
researchProduct